Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 1 to 10 of 261 total matches.
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
contraception during treatment with sotatercept and
for 4 months after stopping the drug.
No data ...
The FDA has approved sotatercept-csrk (Winrevair –
Merck), a first-in-class activin signaling inhibitor, to
increase exercise capacity, improve WHO functional
class, and reduce the risk of clinical worsening
events in adults with WHO Group 1 pulmonary arterial
hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5 doi:10.58347/tml.2024.1702a | Show Introduction Hide Introduction
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
, including warfarin and
oral contraceptives. Concomitant use of sarilumab
and another biologic drug ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
with reproductive potential should use effective
contraception during treatment with eflornithine and
for 1 week ...
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine
decarboxylase inhibitor, has been approved by the
FDA to reduce the risk of relapse in children and with
high-risk neuroblastoma who had at least a partial
response to prior multiagent, multimodality therapy,
including anti-GD2 immunotherapy. About 40-50%
of neuroblastoma cases are classified as high-risk
and they account for ~15% of all pediatric cancer
deaths. Eflornithine is the first drug to be approved
to reduce the risk of relapse in children with high-risk
neuroblastoma. Eflornithine was previously available
in the US...
Med Lett Drugs Ther. 2024 May 13;66(1702):e81-2 doi:10.58347/tml.2024.1702f | Show Introduction Hide Introduction
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
and males with female partners of
reproductive potential should use effective
contraception during ...
Erdafitinib (Balversa – Janssen), an oral kinase
inhibitor, has received full approval from the FDA
for treatment of locally advanced or metastatic
urothelial carcinoma in adults with susceptible
FGFR3 (fibroblast growth factor receptor) genetic
alterations who had disease progression on or after
at least one prior line of systemic therapy. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death receptor-1) or PD-L1 (programmed death-ligand
1) inhibitor therapy. Erdafitinib is the first
oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4 doi:10.58347/tml.2024.1702g | Show Introduction Hide Introduction
Tepotinib (Tepmetko) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
was teratogenic. Females with
reproductive potential and their male partners
should use effective contraception ...
The FDA has granted regular approval to the oral
kinase inhibitor tepotinib (Tepmetko – EMD Serono)
for treatment of adults with metastatic non-small
cell lung cancer (NSCLC) harboring mesenchymal-epithelial
transition (MET) exon 14 skipping
alterations. MET exon 14 skipping mutations occur
in 3-4% of NSCLC cases and are associated with
advanced disease and a poor prognosis. Tepotinib
received accelerated approval for the same indication
in 2021 based on initial overall response rates and
duration of response.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e73-4 doi:10.58347/tml.2024.1701f | Show Introduction Hide Introduction
Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
of hormonal contraceptives.
▶ Dosage: 120 mg once daily until disease progression or
unacceptable toxicity ...
Belzutifan (Welireg – Merck), a first-in-class hypoxia-inducible
factor inhibitor, has been approved by the
FDA for treatment of advanced renal cell carcinoma
(RCC) in adults who received prior treatment with a
programmed death receptor-1 (PD-1) or programmed
death-ligand 1 (PD-L1) inhibitor and a vascular
endothelial growth factor tyrosine kinase inhibitor
(VEGF-TKI). Belzutifan was previously approved for
use in patients with von Hippel-Lindau disease.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-6 doi:10.58347/tml.2024.1701g | Show Introduction Hide Introduction
Donislecel (Lantidra) for Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
that they
are not pregnant before receiving donislecel. They
should use an effective method of contraception before ...
The FDA has approved donislecel-jujn (Lantidra –
CellTrans), an allogeneic pancreatic islet
cellular therapy, for use in conjunction with
immunosuppression for treatment of adults with
type 1 diabetes who are unable to approach target
HbA1c because of current repeated episodes of
severe hypoglycemia despite intensive diabetes
management and education. Donislecel is the first
cell-based treatment to be approved in the US for
type 1 diabetes.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):63-4 doi:10.58347/tml.2024.1700d | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
the efficacy of oral contraceptives.
3A4 substrate; dosage of carbamazepine may need to be adjusted when used ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
contraception while taking capivasertib
and for one month (women) or 4 months (men) after
stopping the drug ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
and their male partners should use effective
nonhormonal contraception during treatment with
repotrectinib ...
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase inhibitor
to be approved for this indication in the US; crizotinib
(Xalkori) and entrectinib (Rozlytrek) were approved
earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7 doi:10.58347/tml.2024.1696g | Show Introduction Hide Introduction